US stock futures dip as Trump’s firing of Cook sparks Fed independence fears
In recent filings with the Securities and Exchange Commission, CTT Pharmaceutical (TADAWUL:2070) Holdings, Inc. (OTC:CTTH) reported that its CEO, Ryan Khouri, has acquired an additional 15,510 shares of the company. The purchase, completed on March 31, 2025, was made at a price of $0.05 per share, amounting to a total transaction value of $775. The transaction occurred at the current market price, with the stock trading near its 52-week range of $0.01 to $0.15. According to InvestingPro, the company maintains a market capitalization of $2.82M and shows a high shareholder yield. Following this acquisition, Khouri’s total direct ownership stands at 6,590,416 shares. This transaction reflects the CEO’s ongoing commitment to the company amidst its operations in the gold and silver ores sector. InvestingPro analysis reveals the company trades at a low Price/Book multiple, with an overall Financial Health rating of FAIR. Subscribers can access 8 additional exclusive ProTips and detailed valuation metrics for CTTH.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.